Wall Street analysts predict that AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) will post sales of $790,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for AVEO Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $1.08 million. AVEO Pharmaceuticals posted sales of $430,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 83.7%. The firm is scheduled to issue its next earnings results on Tuesday, August 6th.

On average, analysts expect that AVEO Pharmaceuticals will report full year sales of $10.62 million for the current year, with estimates ranging from $2.00 million to $24.30 million. For the next year, analysts forecast that the company will report sales of $18.18 million, with estimates ranging from $3.60 million to $30.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AVEO Pharmaceuticals.

AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. The company had revenue of $1.48 million for the quarter, compared to analyst estimates of $2.48 million. AVEO Pharmaceuticals had a net margin of 70.30% and a negative return on equity of 20.94%.

AVEO has been the topic of several recent research reports. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Tuesday, March 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $3.00 target price (down previously from $5.00) on shares of AVEO Pharmaceuticals in a research note on Thursday, January 31st. HC Wainwright reaffirmed a “hold” rating and issued a $1.00 target price on shares of AVEO Pharmaceuticals in a research note on Monday, March 18th. BidaskClub upgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Finally, ValuEngine downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 31st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. AVEO Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $1.96.

Shares of NASDAQ AVEO traded down $0.08 during mid-day trading on Monday, hitting $0.82. The company’s stock had a trading volume of 4,467,232 shares, compared to its average volume of 6,300,979. The firm has a market capitalization of $134.99 million, a PE ratio of -4.30 and a beta of 1.21. AVEO Pharmaceuticals has a one year low of $0.49 and a one year high of $3.59.

In other news, major shareholder Equity Opportunities Fu Growth purchased 4,347,827 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were acquired at an average cost of $1.14 per share, for a total transaction of $4,956,522.78. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 4.40% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. NEA Management Company LLC raised its position in shares of AVEO Pharmaceuticals by 11.8% in the 4th quarter. NEA Management Company LLC now owns 20,896,038 shares of the biopharmaceutical company’s stock valued at $33,434,000 after acquiring an additional 2,198,000 shares during the period. BlackRock Inc. raised its position in shares of AVEO Pharmaceuticals by 3.3% in the 4th quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock valued at $11,773,000 after acquiring an additional 236,822 shares during the period. Vanguard Group Inc raised its holdings in AVEO Pharmaceuticals by 1.5% during the 3rd quarter. Vanguard Group Inc now owns 5,066,360 shares of the biopharmaceutical company’s stock worth $16,770,000 after buying an additional 73,519 shares during the period. Vanguard Group Inc. raised its holdings in AVEO Pharmaceuticals by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,066,360 shares of the biopharmaceutical company’s stock worth $16,770,000 after buying an additional 73,519 shares during the period. Finally, Geode Capital Management LLC raised its holdings in AVEO Pharmaceuticals by 36.3% during the 4th quarter. Geode Capital Management LLC now owns 1,394,576 shares of the biopharmaceutical company’s stock worth $2,231,000 after buying an additional 371,327 shares during the period. Institutional investors and hedge funds own 30.92% of the company’s stock.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

See Also: What are earnings reports?

Get a free copy of the Zacks research report on AVEO Pharmaceuticals (AVEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.